Vigabatrin for Epileptic Spasms and Tonic Seizures in Tuberous Sclerosis Complex.

Abstract

Vigabatrin is recommended as first-line treatment for infantile spasms in tuberous sclerosis complex (TSC), but other indications in children with tuberous sclerosis complex are less known. We retrospectively reviewed 201 children with tuberous sclerosis complex, and identified 21 children older than 1 year started on vigabatrin for any indication and with sufficient follow-up data. The indication for vigabatrin was epileptic spasms (n = 13), tonic seizures (n = 5), both (n = 2), and status epilepticus (n = 1). Mean age of treatment onset was 4.0 years (range 1.1-18.3). All but 1 patient had a reduction in seizures. Ten patients became seizure free and 4 had an improvement of >90%. In 9 patients, vigabatrin was tapered successfully after 8 to 33 months. Side effects reported included rash (n = 1) and behavioral decline (n = 1). No retinal toxicity was detected in 14 of 21 patients with adequate ophthalmologic surveillance data. In conclusion, vigabatrin may be an effective treatment for epileptic spasms and tonic seizures beyond the infantile age.

• Authors: Emma A van der Poest Clement, Mustafa Sahin, Jurriaan M Peters
• Journal: Journal of child neurology (J Child Neurol) Vol. 33 Issue 8 Pg. 519-524 (07 2018) ISSN: 1708-8283 [Electronic] United States
• PMID: 29687739 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)

Chemical References

• Anticonvulsants
• Vigabatrin

Topics

• Adolescent
• Anticonvulsants (therapeutic use)
• Brain (drug effects, physiopathology)
• Child
• Child, Preschool
• Epilepsy (drug therapy, etiology, physiopathology)
• Female
• Follow-Up Studies
• Humans
• Infant
• Male
• Retrospective Studies
• Seizures (drug therapy, etiology, physiopathology)
• Treatment Outcome
• Tuberous Sclerosis (complications, drug therapy, physiopathology)
• Vigabatrin (therapeutic use)